Madrigal Pharmaceuticals, Inc.MDGLNASDAQ
Loading
Year-over-year SG&A expense growth
3Y CAGR
-9.5%/yr
Quarterly compound
5Y CAGR
+5.1%/yr
Recent deceleration
Percentile
P49
Within normal range
vs 5Y Ago
1.3x
Solid growth
Streak
1 qtr
Consecutive growthStable
| Period | Value |
|---|---|
| Q4 2025 | 14.76% |
| Q3 2025 | 6.23% |
| Q2 2025 | 17.26% |
| Q1 2025 | 18.87% |
| Q4 2024 | 31.27% |
| Q3 2024 | 2.03% |
| Q2 2024 | 30.50% |
| Q1 2024 | 73.63% |
| Q4 2023 | 68.71% |
| Q3 2023 | 54.57% |
| Q2 2023 | 10.28% |
| Q1 2023 | 11.16% |
| Q4 2022 | 19.90% |
| Q3 2022 | 3.12% |
| Q2 2022 | 21.91% |
| Q1 2022 | -17.54% |
| Q4 2021 | 41.33% |
| Q3 2021 | -18.03% |
| Q2 2021 | 40.24% |
| Q1 2021 | 17.68% |
| Q4 2020 | 11.50% |
| Q3 2020 | -2.57% |
| Q2 2020 | 22.45% |
| Q1 2020 | -8.70% |
| Q4 2019 | 6.23% |
| Q3 2019 | -33.22% |
| Q2 2019 | 23.74% |
| Q1 2019 | 2.92% |
| Q4 2018 | 9.00% |
| Q3 2018 | 88.52% |
| Q2 2018 | 45.22% |
| Q1 2018 | -22.01% |
| Q4 2017 | 22.71% |
| Q3 2017 | 20.46% |
| Q2 2017 | -4.25% |
| Q1 2017 | -24.06% |
| Q4 2016 | -64.49% |
| Q3 2016 | 75.00% |
| Q2 2016 | 18.16% |
| Q1 2016 | -3.00% |